AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Medical technology company, Next Science Limited (ASX:NXS) is based in Sydney, Australia, and has a research and development centre in Florida, USA. The company is currently engaged in the development and continued commercialisation of its proprietary XbioTM non-toxic technology that eradicates both biofilm-based and free-floating bacterial infections in humans and provides targeted therapy with no known antimicrobial resistance.
Four of Next Scienceâs existing products that have already been introduced in the US market with FDA clearance include â Bactisureâ¢, BlastXâ¢, SurgX⢠and TorrentXâ¢. For Acne Gel, exclusive distribution through Advanced Skin Technologyâs clinic network with non-exclusive online sales in AU/NZ is expected to commence in H2 2019.
Source: Investor Presentation
On 27 May 2019, Next Science announced that it had appointed US-based Grace Medical, a recognised global market leader in the ear, nose and throat (ENT) marketplace, as an exclusive distributor of Next Scienceâs Sinus Lavage. Under the agreement, Grace Medical would exclusively promote, market, distribute and sell Sinus Lavage for use as a medical device in human rhinology and airway procedures.
Grace Medical would be commencing distribution of Sinus Lavage through its extensive networks across Europe, Australia, United States and other key markets, following receipt of the necessary regulatory approvals for the product. In addition, Next Science expects to submit the Sinus Lavage for FDA approval through the 510(k) pathway, and for CE Mark approval, in 2019.
Besides, Next Science currently has multiple other products under its development pipeline (across medical devises, OTC drugs and prescription pharmaceuticals) which includes distribution agreements in discussion for MIS Lavage (minimally invasive surgery) and Middle Ear Wash.
Source: Investor Presentation
Next Science debuted on the Australian Securities Exchange (ASX) on 18 April 2019 after its IPO offer closed early on 19 March 2019. Under the IPO, the company raised around $ 35 million via the issue of 35,000,010 shares at an issue price of $ 1.00 each. The proceeds were indicated to be utilised for expanding the companyâs product development activities, for administration costs and working capital, and to pay for the cost of the offer.
To date, the companyâs substantial shareholders include:
| Shareholders | Interest |
| Auckland Trust Company Ltd* | 25.96% |
| Walker Group Holdings Pty Ltd* | 16.46% |
| Matthew Myntti (Founder & CTO) | 11.53% |
| Judith Mitchell (Managing Director) | 2.64% |
| Total Board & Management Shareholdings | 15.4% |
Source: Companyâs Presentation
With a current market capitalisation of around $496.27 million and approximately 178.51 million outstanding shares, the NXS stock settled the dayâs trading (27 May 2019) at $ 3.380, zooming up 21.58% by $ 0.600 with ~ 5.02 million shares traded. Since its listing on ASX, the stock has skyrocketed by ~106%.
Source: Investor Presentation
In its Investor Presentation released on 27 May 2019, the company emphasised that its products touch a breadth of applications across many medical specialties as they address the issues of chronic infection. A snapshot of the large market opportunity in the United States is illustrated below:
Source: Investor Presentation
As for the Year-to-date business update for FY 2019, strong sales continued in the current year as per the company, as per the company. While BlastX distribution transitioned to the 3M sales force in Q1 2019, there was 61% growth in the sales of Bactisure as compared to the prior YTD period.
Source: Investor Presentation
Going forth, sales growth is expected to accelerate on the back of compounding growth drivers such as increased US market penetration, geographic expansion of sales outside the US (Canada Q3 FY19, Australia Q4 FY19, Europe CE submitted) and the extension of technology into applications outside human health and other active initiatives.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
